All In Biotech

Drug Trial Radar · NCT02229851

Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency.

A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With Growth Hormone Deficiency for 35 Weeks, Followed by a 53-week Open-label Extension Period

Last checked: Nov 20, 2026Latest source record: Nov 23, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

301

Actual

Start

Oct 31, 2014

Primary completion

Apr 21, 2017

Study completion May 7, 2018

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 3, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 23 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted globally. The purpose is to demonstrate the efficacy of once weekly dosing of NNC0195-0092 (somapacitan) compared to placebo and once-daily dosing of somatropin (human growth hormone, hGH) after 35 weeks of treatment in adults with growth hormone deficiency.

Conditions

  • Growth Hormone Disorder
  • Adult Growth Hormone Deficiency

Interventions

  • somapacitanDrug

    Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.

  • somatropinDrug

    Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.

  • placeboDrug

    Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Truncal Fat Percentage (Week 34)Time frame: Week -3, week 34

Locations

117 sites in 19 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Los Angeles, California

  • Novo Nordisk Investigational Site

    Aurora, Colorado

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Roswell, Georgia

  • Novo Nordisk Investigational Site

    Topeka, Kansas

  • Novo Nordisk Investigational Site

    Baltimore, Maryland

  • Novo Nordisk Investigational Site

    Boston, Massachusetts

  • Novo Nordisk Investigational Site

    East Lansing, Michigan

  • Novo Nordisk Investigational Site

    St Louis, Missouri

  • Novo Nordisk Investigational Site

    Omaha, Nebraska

  • Novo Nordisk Investigational Site

    Omaha, Nebraska

  • Novo Nordisk Investigational Site

    Las Vegas, Nevada

  • Novo Nordisk Investigational Site

    Reno, Nevada

  • Novo Nordisk Investigational Site

    New York, New York

  • Novo Nordisk Investigational Site

    Cleveland, Ohio

  • Novo Nordisk Investigational Site

    Portland, Oregon

  • Novo Nordisk Investigational Site

    Philadelphia, Pennsylvania

  • Novo Nordisk Investigational Site

    Philadelphia, Pennsylvania

  • Novo Nordisk Investigational Site

    Pittsburgh, Pennsylvania

  • Novo Nordisk Investigational Site

    El Paso, Texas

  • Novo Nordisk Investigational Site

    Houston, Texas

  • Novo Nordisk Investigational Site

    Plano, Texas

  • Novo Nordisk Investigational Site

    San Antonio, Texas

  • Novo Nordisk Investigational Site

    Shavano Park, Texas

  • Novo Nordisk Investigational Site

    Salt Lake City, Utah

  • Novo Nordisk Investigational Site

    Federal Way, Washington

  • Novo Nordisk Investigational Site

    Seattle, Washington

  • Novo Nordisk Investigational Site

    Blacktown, New South Wales, Australia

  • Novo Nordisk Investigational Site

    Coffs Harbour, New South Wales, Australia

  • Novo Nordisk Investigational Site

    Darlinghurst, New South Wales, Australia

  • Novo Nordisk Investigational Site

    St Leonards, New South Wales, Australia

  • Novo Nordisk Investigational Site

    Woolloongabba, Queensland, Australia

  • Novo Nordisk Investigational Site

    Box Hill, Victoria, Australia

  • Novo Nordisk Investigational Site

    Parkville, Victoria, Australia

  • Novo Nordisk Investigational Site

    Nedlands, Western Australia, Australia

  • Novo Nordisk Investigational Site

    São Paulo, São Paulo, Brazil

  • Novo Nordisk Investigational Site

    Aachen, Germany

  • Novo Nordisk Investigational Site

    Berlin, Germany

Showing 40 of 117 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.